Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies.
作者: Ozoya Oluwatobi OSokol LubomirDalia Samir
作者单位: 1Emergency and Trauma Center, Tampa General Hospital, Tampa, FL, USA.
2Department of Hematological Malignancies, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
3Oncology and Hematology, Mercy Clinic Joplin, Joplin, MO, USA.
刊名: Journal of clinical and translational hepatology, 2016, Vol.4 (2), pp.143-50
来源数据库: PubMed Journal
DOI: 10.14218/JCTH.2016.00005
关键词: Anti-CD20 antibodyBest practice advisoriesHBV reactivationHepatitis B virusNon-Hodgkin’s lymphomaRituximab
原始语种摘要: Hepatitis B virus (HBV) infection remains an endemic disease in most parts of the world despite available prophylactic vaccines. Non-Hodgkin's lymphoma is the most common hematological malignancy, and certain patients undergoing therapy are at increased risk of HBV reactivation. Rituximab, a monoclonal antibody, is well studied in HBV reactivation, but newer agents have been implicated as well. Here, we review novel agents suspected in HBV reactivation and effective strategies to prevent HBV reactivation. Fifteen years of literature were reviewed in order to better understand the reactivation rates of hepatitis B in patients with non-Hodgkin's lymphoma. Anti-CD20 antibodies continue to be the main medications that can lead to HBV reactivation, and HBV reactivation rates have decreased...
全文获取路径: PubMed  (合作)

  • reactivation 再活化
  • lymphoma 淋巴瘤
  • hematological 血液学的
  • aggressive 侵蚀的
  • despite 不管
  • novel 长篇小说
  • antibody 抗体
  • remains 残渣
  • potent 强大的
  • monoclonal 单细胞系的